SONN: רווח נקי למניה (EPS TTM) Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics (SONN) relies on a virtual model, outsourcing manufacturing and clinical operations to external partners. The 12-month net income per share trend links this approach to the company's reputation as a developer of innovative cytokine delivery systems. The value of -8.28 indicates the current metric level, while the absence of commercial sales and a focus on early-stage development create high binary risks.
פילוחי נתונים אנליטיים מרוכזים עבור Sonnet BioTherapeutics (SONN)

Analyzing the EPS TTM history allows us to assess the financial stability of the biotechnology sector. This metric reflects the adjusted net income per share over a trailing twelve-month period, eliminating reporting lags. It demonstrates a company's ability to service debt during a period of high Fed rates. For Sonnet BioTherapeutics (SONN), this indicator determines the investment efficiency of its targeted drug delivery platform. The earnings trend confirms the viability of the selective tumor therapy model.